Pitfalls in Clinical Trials and Future Directions

  • Philip A. Philip
  • Lance K. Heilbrun
  • Judith Abrams
Part of the M. D. Anderson Solid Tumor Oncology Series book series (MDA)

Out of every 100 patients with newly diagnosed pancreatic cancer, only a handful is considered to be cured of the disease. The median survival of patients with advanced pancreatic cancer remains at <6 months. This highlights the significance of overt and micrometastases in this disease. Improvements in the survival of patients with pancreatic cancer depends on future advances in systemic therapies. Unfortunately, therapy of pancreatic cancer has not made the major headway seen with the treatment of other nonhematologic cancers, such as breast and colon. This is not to dismiss the relentless research efforts over the past decade or so that involved a large number of phase II trials and over a dozen well-conducted phase III trials. Clinical trials during the 1990s and early 2000s focused on the addition of newer agents to gemcitabine. Drugs tested included different classes of cytotoxics and more recently biological agents. Despite some interesting results in phase II settings, the translation of benefit to phase III testing was absent with one or two exceptions.

There is growing pressure from within and without pancreas research groups to improve the efficacy of clinical drug development in pancreatic cancer. This chapter discusses some of the issues related to existing experimental designs and challenges to clinical and translational research in this disease. The discussion points are partly generic in that they also pertain to research in other nonhematologic cancers.


Vascular Endothelial Growth Factor Pancreatic Cancer Clin Oncol Advanced Pancreatic Cancer Single Agent Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Braiteh F, Kurzrock R, 2007, Uncommon tumors and exceptional therapies: paradox or paradigm? Mol Cancer Ther 6:1175–1179.CrossRefPubMedGoogle Scholar
  2. 2.
    Deramaudt T, Rustgi AK, 2005, Mutant K-ras in the initiation of pancreatic cancer. Biochim Biophys Acta 1756: 97–101.PubMedGoogle Scholar
  3. 3.
    Furukawa T, Sunamura M, Horii A, 2006, Molecular mechanisms of pancreatic carcinogenesis. Cancer Sci 97:1–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Overholser JP, Prewett MC, Hooper AT, 2000, Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 89:74–82.CrossRefPubMedGoogle Scholar
  5. 5.
    Bruns CJ, Harbison MT, Davis DW, 2000, Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing ortho-topically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 6:1936–1948.PubMedGoogle Scholar
  6. 6.
    Moore MJ, Goldstein D, Hamm J, 2007, Erlotinib plus gemcitabine compared with gemcitab-ine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966.CrossRefPubMedGoogle Scholar
  7. 7.
    Herbst RS, Prager D, Hermann R, 2005, TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892–5899.CrossRefPubMedGoogle Scholar
  8. 8.
    Shepherd FA, Rodrigues PJ, 2005, Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132.CrossRefPubMedGoogle Scholar
  9. 9.
    Roberts TG, Jr. , Lynch TJ, Jr., Chabner BA, 2003, The phase III trial in the era of targeted therapy: unraveling the “go or no go” decision. J Clin Oncol 21:3683–3695.CrossRefPubMedGoogle Scholar
  10. 10.
    Therasse P, Arbuck SG, Eisenhauer EA, 2000, New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216.CrossRefPubMedGoogle Scholar
  11. 11.
    Schilsky RL. 2002, End points in cancer clinical trials and the drug approval process. Clinical Cancer Res 8:935–938.Google Scholar
  12. 12.
    Freidlin B, Korn EL, Hunsberger S, 2007, Proposal for the use of progression-free survival in unblinded randomized trials. J Clin Oncol 25:2122–2126.CrossRefPubMedGoogle Scholar
  13. 13.
    Karrison TG, Maitland ML, Stadler WM, 2007, Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non-small-cell lung cancer. J Natl Cancer Inst 99:1455–1461.CrossRefPubMedGoogle Scholar
  14. 14.
    Taylor JMG, Braun TM, Li Z, 2006, Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design. Clin Trials 3:335–348.PubMedGoogle Scholar
  15. 15.
    Stone A, Wheeler C, Barge A, 2007, Improving the design of phase II trials of cytostatic anti-cancer agents. Contemp Clin Trials 28:138–145.CrossRefPubMedGoogle Scholar
  16. 16.
    Rubinstein LV, Korn EL, Freidlin B, 2005, Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol 23:7199–7206.CrossRefPubMedGoogle Scholar
  17. 17.
    Kindler HL, Friberg G, Singh DA, 2005, Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23: 8033–8040.CrossRefPubMedGoogle Scholar
  18. 18. Kindler HL, Niedzwiecki D, Hollis D, 2007, A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB). ASCO Meeting Abstracts 25: 4508.Google Scholar
  19. 19.
    Liu PY, LeBlanc M, Desai M, 1999, False positive rates of randomized phase II designs. Control Clin Trials 20:343–352.CrossRefPubMedGoogle Scholar
  20. 20. Rosner GL, Stadler W, Ratain MJ, Randomized discontinuation design: application to cytostatic antineoplastic agents. 2002, 20:4478-4484.Google Scholar
  21. 21.
    Boeck S, Hinke A, Wilkowski R, 2007, Importance of performance status for treatment out-come I advanced pancreatic cancer. World J Gastroenterol 13:224–227.PubMedGoogle Scholar
  22. 22.
    Sargent DJ, Conley BA, Alegra C, 2005, Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 23:2020–2027.CrossRefPubMedGoogle Scholar
  23. 23.
    Mishra G, 2006, DNA analysis of cells obtained from endoscopic ultrasound-fine needle aspiration in pancreatic adenocarcinoma: fool’s gold, Pandora’s box, or holy grail? Am J Gastroenterol 101:2501–2503.PubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2008

Authors and Affiliations

  • Philip A. Philip
    • 1
  • Lance K. Heilbrun
    • 1
  • Judith Abrams
    • 1
  1. 1.Karmanos Cancer InstituteWayne State UniversityDetroitUSA

Personalised recommendations